Scientists have taken a significant step toward neutralizing Epstein-Barr virus. Scientists at Fred Hutch Cancer Center have reported an important advance in the effort to stop Epstein Barr virus (EBV ...
EMA validates Type II Variation marketing application for Enhertu as post-neoadjuvant treatment for patients with HER2 positive earlybreast cancer: Tokyo Saturday, February 21, 20 ...
A concise, high-yield guide to cholesterol-lowering therapies—statins, Zetia, PCSK9 inhibitors, bempedoic acid, berberine, ...
Morning Overview on MSN
World’s 1st targeted sepsis treatment hailed as potential lifesaving breakthrough
Grand Pharmaceutical Group Limited announced that its experimental drug STC3141 met the primary clinical endpoint in a Phase ...
Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results